Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Yong Kyun Cho  (Cho YK) 1 Article
Obesity and Metabolism
Tumor Necrosis Factor-α as a Predictor for the Development of Nonalcoholic Fatty Liver Disease: A 4-Year Follow-Up Study
Yun Yong Seo, Yong Kyun Cho, Ji-Cheol Bae, Mi Hae Seo, Se Eun Park, Eun-Jung Rhee, Cheol-Young Park, Ki-Won Oh, Sung-Woo Park, Won-Young Lee
Endocrinol Metab. 2013;28(1):41-45.   Published online March 25, 2013
DOI: https://doi.org/10.3803/EnM.2013.28.1.41
  • 5,263 View
  • 36 Download
  • 63 Crossref
AbstractAbstract PDFPubReader   
Background

Tumor necrosis factor (TNF)-α is associated with insulin resistance and systemic inflammatory responses. The aim of this study was to investigate the relationship between TNF-α and the development of nonalcoholic fatty liver disease (NAFLD) in a longitudinal study.

Methods

Three hundred and sixty-three apparently healthy subjects (mean age, 40.5±6.1 years; male, 57.6%) without NAFLD were enrolled in 2003. Anthropometric and laboratory measurements were performed. The participants were grouped into tertiles according to their serum TNF-α levels from samples taken in 2003. At a 4-year follow-up, we compared the odds ratios (ORs) of the development of NAFLD according to the tertiles of TNF-α levels measured in 2003.

Results

At the 4-year follow-up, the cumulative incidence of NAFLD was 29.2% (106/363). The group that developed NAFLD had higher levels of TNF-α than those in the group without NAFLD (3.65±1.79 pg/mL vs. 3.15±1.78 pg/mL; P=0.016). When the 2003 serum TNF-α levels were categorized into tertiles: incidence of NAFLD observed in 2007 was significantly higher with increasing tertiles (22.6%, 35.8%, and 41.5%, respectively; P<0.05). The risk of developing NAFLD was significantly greater in the highest tertile of TNF-α than in the lowest tertile after adjusting for age, smoking, and BMI (OR, 2.20; 95% confidence interval, 1.12 to 4.01; P<0.05).

Conclusion

Higher serum TNF-α levels in subjects without NAFLD were associated with the development of NAFLD. The results of study might suggest a pathologic role of inflammation in NAFLD.

Citations

Citations to this article as recorded by  
  • NAFLD Is Associated With Quiescent Rather Than Active Crohn’s Disease
    Scott McHenry, Matthew Glover, Ali Ahmed, Quazim Alayo, Maria Zulfiqar, Daniel R Ludwig, Matthew A Ciorba, Nicholas O Davidson, Parakkal Deepak
    Inflammatory Bowel Diseases.2024; 30(5): 757.     CrossRef
  • Nigella sativa Efficacy in Non-alcoholic Fatty Liver Disease: Mechanisms and Clinical Effects
    A.A. Sangouni, A. Jamalzehi, M. Moradpour, H. Mozaffari-Khosravi
    Journal of Herbal Medicine.2024; 43: 100833.     CrossRef
  • Berberine prevents NAFLD and HCC by modulating metabolic disorders
    Xinyue Lin, Juanhong Zhang, Yajun Chu, Qiuying Nie, Junmin Zhang
    Pharmacology & Therapeutics.2024; 254: 108593.     CrossRef
  • Antitumor Mechanisms of Lycium barbarum Fruit: An Overview of In Vitro and In Vivo Potential
    Maria Rosaria Miranda, Vincenzo Vestuto, Giuseppina Amodio, Michele Manfra, Giacomo Pepe, Pietro Campiglia
    Life.2024; 14(3): 420.     CrossRef
  • Theabrownin alleviates nonalcoholic fatty liver disease by inhibiting the intestinal farnesoid X receptor–ceramide axis
    Jieyi Wang, Dan Zheng, Kun Ge, Fengjie Huang, Yang Li, Xiaojiao Zheng, Wei Jia, Aihua Zhao
    Food Frontiers.2024; 5(4): 1559.     CrossRef
  • Necroptosis contributes to non-alcoholic fatty liver disease pathoetiology with promising diagnostic and therapeutic functions
    Hong-Ju Sun, Bo Jiao, Yan Wang, Yue-Hua Zhang, Ge Chen, Zi-Xuan Wang, Hong Zhao, Qing Xie, Xiao-Hua Song
    World Journal of Gastroenterology.2024; 30(14): 1968.     CrossRef
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • The role of gut microbiota augmentation in managing non-alcoholic fatty liver disease: an in-depth umbrella review of meta-analyses with grade assessment
    Gautam Maddineni, Sri J. Obulareddy, Ruchir D. Paladiya, Rohan R. Korsapati, Shika Jain, Herby Jeanty, Fnu Vikash, Nayanika C. Tummala, Samatha Shetty, Arezoo Ghazalgoo, Abinash Mahapatro, Viswanadh Polana, Dhruvan Patel
    Annals of Medicine & Surgery.2024; 86(8): 4714.     CrossRef
  • Caffeine mitigates tamoxifen-induced fatty liver in Wistar rats
    Yasin Sezgin, Ejder Saylav Bora, Duygu Burcu Arda, Yiğit Uyanikgil, Oytun Erbaş
    Acta Cirúrgica Brasileira.2024;[Epub]     CrossRef
  • RGS7-ATF3-Tip60 Complex Promotes Hepatic Steatosis and Fibrosis by Directly Inducing TNFα
    Madhuri Basak, Kiran Das, Tarun Mahata, Abhishek Singh Sengar, Sumit Kumar Verma, Sayan Biswas, Kakali Bhadra, Adele Stewart, Biswanath Maity
    Antioxidants & Redox Signaling.2023; 38(1-3): 137.     CrossRef
  • The capsaicinoid nonivamide suppresses the inflammatory response and attenuates the progression of steatosis in a NAFLD‐rat model
    Naruemon Wikan, Jiraporn Tocharus, Chio Oka, Sivanan Sivasinprasasn, Waraluck Chaichompoo, Apichart Suksamrarn, Chainarong Tocharus
    Journal of Biochemical and Molecular Toxicology.2023;[Epub]     CrossRef
  • Thermoneutral housing shapes hepatic inflammation and damage in mouse models of non-alcoholic fatty liver disease
    Jarren R. Oates, Keisuke Sawada, Daniel A. Giles, Pablo C. Alarcon, Michelle S.M.A. Damen, Sara Szabo, Traci E. Stankiewicz, Maria E. Moreno-Fernandez, Senad Divanovic
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • 1,25-Dihydroxycholecalciferol down-regulates 3-mercaptopyruvate sulfur transferase and caspase-3 in rat model of non-alcoholic fatty liver disease
    Maher N. Ibrahim, Abeer A. Khalifa, Dalia A. Hemead, Amira Ebrahim Alsemeh, Marwa A. Habib
    Journal of Molecular Histology.2023; 54(2): 119.     CrossRef
  • Effects of Resveratrol Supplementation on Nonalcoholic Fatty Liver Disease Management
    Arefe Nemati, Zeinab Nikniaz, Ali Mota
    Topics in Clinical Nutrition.2023; 38(2): 144.     CrossRef
  • The effects of chicory supplementation on liver enzymes and lipid profiles in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of clinical evidence
    Elham Maleki, Ali Sadeghpour, Erfan Taherifard, Bahareh Izadi, Mehdi Pasalar, Maryam Akbari
    Clinical Nutrition ESPEN.2023; 55: 447.     CrossRef
  • Using bioinformatics and systems biology methods to identify the mechanism of interaction between COVID-19 and nonalcoholic fatty liver disease
    Wenbo Dong, Yan Jin, Hongshuo Shi, Xuecheng Zhang, Jinshu Chen, Hongling Jia, Yongchen Zhang
    Medicine.2023; 102(23): e33912.     CrossRef
  • The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease
    Ilias D. Vachliotis, Stergios A. Polyzos
    Current Obesity Reports.2023; 12(3): 191.     CrossRef
  • Gene-regulation modules in nonalcoholic fatty liver disease revealed by single-nucleus ATAC-seq
    Fumihiko Takeuchi, Yi-Qiang Liang, Hana Shimizu-Furusawa, Masato Isono, Mia Yang Ang, Kotaro Mori, Taizo Mori, Eiji Kakazu, Sachiyo Yoshio, Norihiro Kato
    Life Science Alliance.2023; 6(10): e202301988.     CrossRef
  • Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review
    Cristian Sandoval, Carolina Reyes, Pamela Rosas, Karina Godoy, Vanessa Souza-Mello, Jorge Farías
    International Journal of Molecular Sciences.2023; 24(21): 15728.     CrossRef
  • Maternal betaine supplementation ameliorates fatty liver disease in offspring mice by inhibiting hepatic NLRP3 inflammasome activation
    Lun Li, Liuqiao Sun, Xiaoping Liang, Qian Ou, Xuying Tan, Fangyuan Li, Zhiwei Lai, Chenghe Ding, Hangjun Chen, Xinxue Yu, Qiongmei Wu, Jun Wei, Feng Wu, Lijun Wang
    Nutrition Research and Practice.2023; 17(6): 1084.     CrossRef
  • Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease
    Yamei Duan, Xiongfeng Pan, Jiayou Luo, Xiang Xiao, Jingya Li, Prince L. Bestman, Miyang Luo
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • A potential link between plasma short‑chain fatty acids, TNF‑α level and disease progression in non‑alcoholic fatty liver disease: A retrospective study
    Jing Xiong, Xia Chen, Zhijing Zhao, Ying Liao, Ting Zhou, Qian Xiang
    Experimental and Therapeutic Medicine.2022;[Epub]     CrossRef
  • Update on Non-Alcoholic Fatty Liver Disease-Associated Single Nucleotide Polymorphisms and Their Involvement in Liver Steatosis, Inflammation, and Fibrosis: A Narrative Review
    Fajar Dwi Astarini, Neneng Ratnasari, Widya Wasityastuti
    Iranian Biomedical Journal.2022; 26(4): 252.     CrossRef
  • Clinical significance of epicardial fat assessment in hypertensive patients with non-alcoholic fatty liver disease
    M. Е. Statsenko, A. M. Streltsova
    "Arterial’naya Gipertenziya" ("Arterial Hypertension").2022; 28(3): 260.     CrossRef
  • The biological clock enhancer nobiletin ameliorates steatosis in genetically obese mice by restoring aberrant hepatic circadian rhythm
    Sebastian Larion, Caleb A. Padgett, Joshua T. Butcher, James D. Mintz, David J. Fulton, David W. Stepp
    American Journal of Physiology-Gastrointestinal and Liver Physiology.2022; 323(4): G387.     CrossRef
  • Effect of Fiber Supplementation on Systemic Inflammation and Liver Steatosis in Mice Fed with High-Carbohydrate Diets
    Cacilda Rocha Hildebrand Budke, Débora Marchetti Chaves Thomaz, Rodrigo Juliano de Oliveira, Rita de Cássia Avellaneda Guimarães, Amariles Diniz Ramires, Doroty Mesquita Dourado, Elisvânia Freitas dos Santos, Adriana Conceicon Guercio Menezes, Andréia Con
    Metabolic Syndrome and Related Disorders.2022; 20(10): 558.     CrossRef
  • Association between inflammatory markers and non-alcoholic fatty liver disease in obese children
    Yamei Duan, Jiayou Luo, Xiongfeng Pan, Jia Wei, Xiang Xiao, Jingya Li, Miyang Luo
    Frontiers in Public Health.2022;[Epub]     CrossRef
  • Efficacy of resveratrol supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials
    Sahar Rafiee, Hamed Mohammadi, Abed Ghavami, Erfan Sadeghi, Zahra Safari, Gholamreza Askari
    Complementary Therapies in Clinical Practice.2021; 42: 101281.     CrossRef
  • Association of xenobiotic-metabolizing enzymes (GSTM1 and GSTT 1), and pro-inflammatory cytokines (TNF-α and IL-6) genetic polymorphisms with non-alcoholic fatty liver disease
    Narges Damavandi, Sirous Zeinali
    Molecular Biology Reports.2021; 48(2): 1225.     CrossRef
  • Potential protective effect of curcumin in high-fat diet-induced nonalcoholic fatty liver disease in rats
    AhmedM M. Mahmouda, NohaA.-R A. El-Hagag, HusseinI El-Bitar, Abdel-HalimM Afifi
    Journal of Current Medical Research and Practice.2021; 6(1): 92.     CrossRef
  • Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease
    Mengyao Zhao, Shumin Chen, Xiaoguo Ji, Xin Shen, Jiangshan You, Xinyi Liang, Hao Yin, Liming Zhao
    Pharmacological Research.2021; 166: 105517.     CrossRef
  • Inflammation in Metabolic Diseases and Insulin Resistance
    Won-Young Lee
    Cardiovascular Prevention and Pharmacotherapy.2021; 3(2): 31.     CrossRef
  • Cellular Mechanisms of Liver Fibrosis
    Pragyan Acharya, Komal Chouhan, Sabine Weiskirchen, Ralf Weiskirchen
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • The role of insulin resistance and systemic inflammation in reducing the elasticity of the main arteries in patients with arterial hypertension and non-alcoholic fatty liver disease
    M.E. Statsenko, A.M. Streltsova, M.I. Turovets
    Profilakticheskaya meditsina.2021; 24(5): 60.     CrossRef
  • Validation of an adipose-liver human-on-a-chip model of NAFLD for preclinical therapeutic efficacy evaluation
    Victoria L. Slaughter, John W. Rumsey, Rachel Boone, Duaa Malik, Yunqing Cai, Narasimhan Narasimhan Sriram, Christopher J. Long, Christopher W. McAleer, Stephen Lambert, Michael L. Shuler, J. J. Hickman
    Scientific Reports.2021;[Epub]     CrossRef
  • L-ergothioneine and metformin alleviates liver injury in experimental type-2 diabetic rats via reduction of oxidative stress, inflammation, and hypertriglyceridemia
    Ayobami Dare, Mahendra L. Channa, Anand Nadar
    Canadian Journal of Physiology and Pharmacology.2021; 99(11): 1137.     CrossRef
  • Patchouli alcohol ameliorates skeletal muscle insulin resistance and NAFLD via AMPK/SIRT1-mediated suppression of inflammation
    Do Hyeon Pyun, Tae Jin Kim, Seung Yeon Park, Hyun Jung Lee, A.M. Abd El-Aty, Ji Hoon Jeong, Tae Woo Jung
    Molecular and Cellular Endocrinology.2021; 538: 111464.     CrossRef
  • Low Vitamin D Level was Associated with Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
    Vahid Sheikhi, Zahra Heidari
    Shiraz E-Medical Journal.2021;[Epub]     CrossRef
  • Inflammation and Fibrogenesis in MAFLD: Role of the Hepatic Immune System
    Pietro Torre, Benedetta Maria Motta, Roberta Sciorio, Mario Masarone, Marcello Persico
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • Sarcopenia Is an Independent Risk Factor for NAFLD in COPD: A Nationwide Survey (KNHANES 2008–2011)


    Kyung Soo Hong, Min Cheol Kim, June Hong Ahn
    International Journal of Chronic Obstructive Pulmonary Disease.2020; Volume 15: 1005.     CrossRef
  • A multi-targeting strategy to ameliorate high-fat-diet- and fructose-induced (western diet-induced) non-alcoholic fatty liver disease (NAFLD) with supplementation of a mixture of legume ethanol extracts
    Yen-Chun Koh, Yen-Cheng Lin, Pei-Sheng Lee, Ting-Jang Lu, Kai-Yi Lin, Min-Hsiung Pan
    Food & Function.2020; 11(9): 7545.     CrossRef
  • The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling
    Samukelisiwe C. Shabalala, Phiwayinkosi V. Dludla, Lawrence Mabasa, Abidemi P. Kappo, Albertus K. Basson, Carmen Pheiffer, Rabia Johnson
    Biomedicine & Pharmacotherapy.2020; 131: 110785.     CrossRef
  • Redox Regulation by Protein S-Glutathionylation: From Molecular Mechanisms to Implications in Health and Disease
    Aysenur Musaogullari, Yuh-Cherng Chai
    International Journal of Molecular Sciences.2020; 21(21): 8113.     CrossRef
  • Long-Term Soy Protein Isolate Consumption Reduces Liver Steatosis Through Changes in Global Transcriptomics in Obese Zucker Rats
    Melisa Kozaczek, Walter Bottje, Byungwhi Kong, Sami Dridi, Diyana Albataineh, Kentu Lassiter, Reza Hakkak
    Frontiers in Nutrition.2020;[Epub]     CrossRef
  • Lycopene Modulates Pathophysiological Processes of Non-Alcoholic Fatty Liver Disease in Obese Rats
    Mariane Róvero Costa, Jéssica Leite Garcia, Carol Cristina Vágula de Almeida Silva, Artur Junio Togneri Ferron, Fabiane Valentini Francisqueti-Ferron, Fabiana Kurokawa Hasimoto, Cristina Schmitt Gregolin, Dijon Henrique Salomé de Campos, Cleverton Roberto
    Antioxidants.2019; 8(8): 276.     CrossRef
  • A new method to induce nonalcoholic steatohepatitis (NASH) in mice
    Feryal Savari, Seyyed Ali Mard, Mohammad Badavi, Anahita Rezaie, Mohammad Kazem Gharib-Naseri
    BMC Gastroenterology.2019;[Epub]     CrossRef
  • Zeaxanthin Dipalmitate in the Treatment of Liver Disease
    Nisma Lena Bahaji Azami, Mingyu Sun
    Evidence-Based Complementary and Alternative Medicine.2019; 2019: 1.     CrossRef
  • A narrative review on effects of vitamin D on main risk factors and severity of Non-Alcoholic Fatty Liver Disease
    Abbas Ali Sangouni, Saeid Ghavamzadeh, Atena Jamalzehi
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(3): 2260.     CrossRef
  • ABO blood group and risk of newly diagnosed nonalcoholic fatty liver disease: A case-control study in Han Chinese population
    Guo-Chao Zhong, Shan Liu, Yi-Lin Wu, Mei Xia, Jin-Xian Zhu, Fa-Bao Hao, Lun Wan, Pavel Strnad
    PLOS ONE.2019; 14(12): e0225792.     CrossRef
  • Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective
    Eun-Jung Rhee
    Endocrinology and Metabolism.2019; 34(3): 226.     CrossRef
  • Telmisartan improves the metabolic, hematological and inflammasome indices in non-alcoholic fatty liver infiltration: A pilot open-label placebo-controlled study
    Marwan S.M. Al-Nimer, Vian A.W. Esmail, O. Mohammad
    Electronic Journal of General Medicine.2019; 16(3): em142.     CrossRef
  • TRUSS Exacerbates NAFLD Development by Promoting IκBα Degradation in Mice
    Chang‐Jiang Yu, Qiu‐Shi Wang, Ming‐Ming Wu, Bin‐Lin Song, Chen Liang, Jie Lou, Liang‐Liang Tang, Xiao‐Di Yu, Na Niu, Xu Yang, Bao‐Long Zhang, Yao Qu, Yang Liu, Zhi‐Chao Dong, Zhi‐Ren Zhang
    Hepatology.2018; 68(5): 1769.     CrossRef
  • Association Between Tumor Necrosis Factor-α and the Risk of Hepatic Events: A Median 3 Years Follow-Up Study
    Zhi Zhu, Shuofeng Li
    Hepatitis Monthly.2018;[Epub]     CrossRef
  • Clinical Characteristics of Non-Alcoholic Fatty Liver Disease Based on Analyses from the Kangbuk Samsung Health Study
    Eun-Jung Rhee
    The Journal of Korean Diabetes.2017; 18(2): 81.     CrossRef
  • Ezetimibe alleviates non-alcoholic fatty liver disease through the miR-16 inhibiting mTOR/p70S6K1 pathway
    Xiang Wang, Yunbing Meng, Junrong Zhang
    RSC Advances.2017; 7(60): 37967.     CrossRef
  • Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease
    Flavia A Cimini, Ilaria Barchetta, Simone Carotti, Laura Bertoccini, Marco G Baroni, Umberto Vespasiani-Gentilucci, Maria-Gisella Cavallo, Sergio Morini
    World Journal of Gastroenterology.2017; 23(19): 3407.     CrossRef
  • Omega-3 Fatty Acids Protect Fatty and Lean Mouse Livers After Major Hepatectomy
    Michael Linecker, Perparim Limani, Patryk Kambakamba, Philipp Kron, Christoph Tschuor, Nicolas Calo, Michelangelo Foti, Jean-François Dufour, Rolf Graf, Bostjan Humar, Pierre-Alain Clavien
    Annals of Surgery.2017; 266(2): 324.     CrossRef
  • Exogenous administration of DLK1 ameliorates hepatic steatosis and regulates gluconeogenesis via activation of AMPK
    Y-h Lee, M R Yun, H M Kim, B H Jeon, B-C Park, B-W Lee, E S Kang, H C Lee, Y W Park, B-S Cha
    International Journal of Obesity.2016; 40(2): 356.     CrossRef
  • Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets
    Feliciano Chanana Paquissi
    Frontiers in Immunology.2016;[Epub]     CrossRef
  • Comparison of Serum Adipocytokine Levels according to Metabolic Health and Obesity Status
    Tae Hoon Lee, Won Seon Jeon, Ki Joong Han, Shin Yeoung Lee, Nam Hee Kim, Hyun Beom Chae, Choel Min Jang, Kyung Mo Yoo, Hae Jung Park, Min Kyung Lee, Se Eun Park, Hyung Geun Oh, Cheol-Young Park, Won-Young Lee, Ki-Won Oh, Sung-Woo Park, Eun-Jung Rhee
    Endocrinology and Metabolism.2015; 30(2): 185.     CrossRef
  • Metabolic Health Is More Important than Obesity in the Development of Nonalcoholic Fatty Liver Disease: A 4-Year Retrospective Study
    Min-Kyung Lee, Eun-Jung Rhee, Min Chul Kim, Byung Sub Moon, Jeong In Lee, Young Seok Song, Eun Na Han, Hyo Sun Lee, Yoonjeong Son, Se Eun Park, Cheol-Young Park, Ki-Won Oh, Sung-Woo Park, Won-Young Lee
    Endocrinology and Metabolism.2015; 30(4): 522.     CrossRef
  • Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease
    Sanja Stojsavljević
    World Journal of Gastroenterology.2014; 20(48): 18070.     CrossRef
  • Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
    Won-Young Lee
    Endocrinology and Metabolism.2014; 29(3): 251.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism
TOP